NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization308.87 mln
Float39.36 mln
Earnings Date05/20/2026
P / E
5.89
Undervalued
Piotroski F-Score
5
/ 9
Neutral
Altman Z-Score
0.45
Distressed
1-Year Estimate
19.57
Transformational upside
Relative Strength
90
/ 100
Top performer
Business Description
Abeona Therapeutics is a US-based biopharmaceutical company focused on developing gene and cell therapies for serious, life-threatening conditions. Its leading product, ZEVASKYN, is designed to treat recessive dystrophic epidermolysis bullosa, a severe skin disorder, while its pipeline includes additional therapies targeting rare eye diseases such as X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. Founded in 1974 and headquartered in Cleveland, Ohio, the company also advances a broader gene therapy platform aimed at addressing other difficult-to-treat conditions.
